Radiopharm Theranostics Limited (ASX:RAD – Get Free Report) insider Riccardo Canevari bought 684,787 shares of the business’s stock in a transaction on Monday, December 16th. The stock was purchased at an average price of A$0.03 ($0.02) per share, for a total transaction of A$19,858.82 ($12,411.76).
Radiopharm Theranostics Stock Performance
Radiopharm Theranostics Company Profile
Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It is developing its lead products comprising Nano-mAbs and AVB6 Integrin. The company was incorporated in 2021 and is based in Carlton, Australia.
See Also
- Five stocks we like better than Radiopharm Theranostics
- What is a Dividend King?
- Dow Jones: A Relevant Benchmark or a Relic of the Past?
- How to Use High Beta Stocks to Maximize Your Investing Profits
- 3 Big-Name Stocks Just Announced Big-Time Dividend Increases
- What Is WallStreetBets and What Stocks Are They Targeting?
- Time to Board Carnival Cruise Lines’ Stock Price Rally
Receive News & Ratings for Radiopharm Theranostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radiopharm Theranostics and related companies with MarketBeat.com's FREE daily email newsletter.
